Date | Price Target | Rating | Analyst |
---|---|---|---|
9/9/2024 | $90.00 | Neutral | JP Morgan |
8/6/2024 | $100.00 | Buy | Stifel |
5/30/2024 | $87.00 | Neutral | Goldman |
2/15/2024 | $100.00 | Buy | HSBC Securities |
2/12/2024 | $66.00 → $88.00 | Sell → Neutral | UBS |
11/30/2023 | $80.00 | Hold | Jefferies |
11/27/2023 | $86.00 → $66.00 | Neutral → Sell | UBS |
9/19/2023 | $82.00 | Buy | Citigroup |
8/25/2023 | $80.00 | Buy | Argus |
8/16/2023 | $90.00 | Overweight | Wells Fargo |
Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy
GE HealthCare Technologies Inc. (NASDAQ:GEHC) (the "Company" or "GE HealthCare") announced today the pricing of the previously announced secondary underwritten public offering (the "Offering") of 15,000,000 shares of its common stock (the "GEHC Shares") at a public offering price of $86.00 per share. The Offering was upsized from the previously announced offering size of 10,000,000 GEHC Shares. GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below). Prior to the closing of the Offering, GE Aerospace (General Electric Company) is expected to exchange
GE HealthCare Technologies Inc. (NASDAQ:GEHC) (the "Company" or "GE HealthCare") announced today the launch of a secondary underwritten public offering (the "Offering") of 10,000,000 shares of its common stock (the "GEHC Shares"). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below). Prior to the closing of the Offering, GE Aerospace (General Electric Company) is expected to exchange the GEHC Shares for indebtedness of GE Aerospace held by Morgan Stanley Bank, N.A. and Morgan Stanley Senior Funding, Inc. (together, the "MS Lenders"), affiliates of
CE mark of these next-generation cardiac imaging systems will further enable connected care along the cardiology patient journey and provide clinicians with the tools to deliver more efficient and timely care Today, GE HealthCare (NASDAQ:GEHC) announced the CE marks of its Vscan Air™ SL wireless handheld ultrasound system with Caption AI™ (Vscan Air SL with Caption AI), an artificial intelligence (AI)-driven software for rapid cardiac assessments at the point of care, as well as ECG-less Cardiac computed tomography (CT) scanning on its Revolution Apex™ platform, which allows clinicians to acquire cardiac images without the aid of the patients' electrocardiogram (ECG) signal/trace. Both
GE HealthCare (NASDAQ:GEHC) announced today that management will present at the following September investor conferences. 2024 Wells Fargo Healthcare Conference in Boston on September 4, 2024 at 10:15 am ET/9:15 am CT Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 5, 2024 at 1:05 pm ET/12:05 pm CT These events can be accessed at the GE HealthCare Investor Relations website: https://investor.gehealthcare.com/news-events/events on the dates and times listed above. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrate
Published in Anesthesia and Analgesia, results from the multi-site trial evaluating End-tidal Control software provide compelling evidence for enhanced accuracy and efficiency of anesthesia delivery compared to conventional anesthetic gas delivery methods.1 End-tidal Control is the first FDA-approved software that automatically adjusts and maintains exhaled oxygen and exhaled anesthetic concentrations, with more accuracy in reaching the clinician's target versus manual control. The utilization of End-tidal Control software reduces manual adjustments by clinicians, enabling them to focus on time with their patients.2 Results support End-tidal Control's ability to reduce anesthetic age
Project aims to increase access of advanced imaging techniques for clinicians to help drive improved diagnosis and management of female pelvic diseases and conditions, such as endometriosis and ovarian cancer. The Center for Translational Imaging and Precision Medicine (CTIPM) at the University of California San Diego School of Medicine will develop new magnetic resonance imaging (MRI) protocols and educational materials for women's imaging. GE HealthCare today announced a collaboration with the University of California San Diego School of Medicine to investigate advanced magnetic resonance imaging (MRI) protocols and techniques for female-specific diseases and conditions of the pelv
Revenues were flat year-over-year; Organic revenue growth* was 1% Net income margin was 8.9% versus 8.7% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 15.3% versus 14.8% Diluted earnings per share (EPS) were $0.93 versus $0.91 for the prior year; Adjusted EPS* was $1.00 versus $0.92 Cash flow from operating activities was $(119) million versus $(67) million for the prior year; Free cash flow* was $(182) million versus $(136) million Company updates full-year guidance for Organic revenue growth* and Adjusted EBIT margin* GE HealthCare (NASDAQ:GEHC) today reported financial results for the second quarter ended June 30, 2024. GE HealthCare
GE HealthCare selects AWS as its strategic cloud provider to deliver entirely new, purpose-built foundation models designed to fast-track the development of innovative healthcare applications GE HealthCare plans to train and deploy clinical foundation models on AWS's machine learning and generative AI technologies to help healthcare providers expedite clinical and operational workflows to improve delivery of care GE HealthCare (NASDAQ:GEHC) and Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ:AMZN), today announced a strategic collaboration to develop purpose-built foundation models and generative artificial intelligence (AI) applications designed to help clinicia
Agreement to acquire business adds innovative, real-time image recognition technology and expertise to GE HealthCare's portfolio of AI-enabled devices AI-based technology from Intelligent Ultrasound aims to provide real-time support for OBGYN scans and improve exam accuracy and efficiency Planned acquisition supports GE HealthCare's precision care strategy to address inefficiencies and improve patient care quality GE HealthCare (NASDAQ:GEHC) today announced it has entered into an agreement to acquire Intelligent Ultrasound Group PLC's (Intelligent Ultrasound) clinical artificial intelligence (AI) software business for total consideration of approximately $51 million. Intelligent U
GE HealthCare (NASDAQ:GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, will announce its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
424B3 - GE HealthCare Technologies Inc. (0001932393) (Filer)
FWP - GE HealthCare Technologies Inc. (0001932393) (Subject)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
144 - GE HealthCare Technologies Inc. (0001932393) (Subject)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
FWP - GE HealthCare Technologies Inc. (0001932393) (Subject)
10-Q - GE HealthCare Technologies Inc. (0001932393) (Filer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
S-3ASR - GE HealthCare Technologies Inc. (0001932393) (Filer)
JP Morgan initiated coverage of GE HealthCare with a rating of Neutral and set a new price target of $90.00
Stifel initiated coverage of GE HealthCare with a rating of Buy and set a new price target of $100.00
Goldman initiated coverage of GE HealthCare with a rating of Neutral and set a new price target of $87.00
HSBC Securities initiated coverage of GE HealthCare with a rating of Buy and set a new price target of $100.00
UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $88.00 from $66.00 previously
Jefferies initiated coverage of GE HealthCare with a rating of Hold and set a new price target of $80.00
UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $66.00 from $86.00 previously
Citigroup initiated coverage of GE HealthCare with a rating of Buy and set a new price target of $82.00
Argus initiated coverage of GE HealthCare with a rating of Buy and set a new price target of $80.00
Wells Fargo initiated coverage of GE HealthCare with a rating of Overweight and set a new price target of $90.00
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
GE HealthCare (NASDAQ:GEHC) today announced it has entered into an agreement to acquire Intelligent Ultrasound Group PLC's (Intelligent Ultrasound) clinical artificial intelligence (AI) software business for total consideration of approximately $51 million. Intelligent Ultrasound is a leader in integrated AI-driven image analysis tools designed to make ultrasound smarter and more efficient. GE HealthCare plans to incorporate these solutions across the ultrasound portfolio, strengthening its capabilities with technology that helps improve workflows and enhance ease-of-use for the benefit of clinicians and patients.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume PFE CALL SWEEP BEARISH 07/19/24 $28.00 $72.8K 28.1K 2.7K MRK CALL SWEEP BEARISH 07/19/24 $140.00 $78.
The U.S. Supreme Court has supported 21 pharmaceutical and medical equipment companies, led by AstraZeneca Plc (NYSE:AZN), in a lawsuit accusing them of funding terrorism that harmed American troops and civilians in Iraq. The justices dismissed a lower court’s ruling that had allowed the case to proceed, directing the court to reconsider the lawsuit. The plaintiffs allege that major U.S. and European pharmaceutical and device manufacturers, including Pfizer Inc (NYSE:PFE), GE Healthcare USA, a unit of GE Healthcare Technologies Inc (NASDAQ:GEHC), Johnson & Johnson (NYSE:JNJ), and F. Hoffmann-La Roche (OTC:RHHBY), provided corrupt payments to the Hezbollah-sponsored militia group Jaysh
Today Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (NASDAQ:GEHC) announced HHNM as the first location in the United States to install GE HealthCare's latest Allia Image Guided System (IGS) Pulse, which was designed to provide exceptional image quality and improve workflow for the diagnosis and treatment of cardiovascular diseases (CVD). HHNM will use the Allia IGS Pulse system in its cardiac electrophysiology (EP) lab to plan, guide and monitor the outcomes of electrophysiological procedures, such as cardiac ablations, cardiac catherizations, transcatheter aortic valve replacements, balloon and coronary angioplasties and more.
Innovative Suite Combines Live Medical Imaging, 3D Anatomy Visualization, And Advanced Imaging Technologies With Remote Collaboration Capabilities
GE HealthCare Techs's (NYSE:GEHC) short percent of float has risen 12.46% since its last report. The company recently reported that it has 11.64 million shares sold short, which is 3.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.29 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short i
On CNBC's “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners said he is making good money in NVIDIA Corporation (NASDAQ:NVDA) and believes he will continue to do so. The chipmaker giant has seen an astounding 186% surge since the end of May 2023, fueled by skyrocketing demand for chips in artificial intelligence development. Stephanie Link of Hightower said she likes GE HealthCare Technologies Inc. (NASDAQ:GEHC). On April 30, GE Healthcare Technologies reported first-quarter sales of $4.6 billion, down 1% Y/Y, and were approximately flat on an Organic basis, with decreased volume partially offset by positive price, missing the consensus of $4.8 billion. Don't forget
Revenues were flat year-over-year; Organic revenue growth* was 1% Net income margin was 8.9% versus 8.7% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 15.3% versus 14.8% Diluted earnings per share (EPS) were $0.93 versus $0.91 for the prior year; Adjusted EPS* was $1.00 versus $0.92 Cash flow from operating activities was $(119) million versus $(67) million for the prior year; Free cash flow* was $(182) million versus $(136) million Company updates full-year guidance for Organic revenue growth* and Adjusted EBIT margin* GE HealthCare (NASDAQ:GEHC) today reported financial results for the second quarter ended June 30, 2024. GE HealthCare
GE HealthCare (NASDAQ:GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, will announce its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global
The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the second quarter of 2024 payable on August 15, 2024 to all shareholders of record as of July 19, 2024. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, con
Revenues declined 1% year-over-year; Organic revenue growth* was approximately flat Net income margin was 8.0% versus 7.9% for the prior year; Adjusted Earnings Before Interest and Taxes (EBIT) margin* was 14.7% versus 14.1% Diluted earnings per share (EPS) were $0.81 versus $0.41 for the prior year; Adjusted EPS* was $0.90 versus $0.85 Cash flow from operating activities was $419 million versus $468 million for the prior year; Free cash flow* was $274 million versus $325 million; repaid $150 million of debt in January 2024 Reaffirming full year 2024 guidance GE HealthCare (NASDAQ:GEHC), a leading global precision care innovator, today reported financial results for the firs
GE HealthCare (NASDAQ:GEHC), a leader in precision care innovation, will announce its first quarter 2024 financial results before the market opens on Tuesday, April 30, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay will also all be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digit
The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the first quarter of 2024 payable on May 15, 2024 to all shareholders of record as of April 19, 2024. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connec
Delivers Strong Financial and Operating Performance in First Year as Public Company Fourth Quarter 2023 Revenue growth was 5% year-over-year; Organic revenue growth* of 5% Net income margin was 7.7% versus 11.2% for the prior year; Adjusted Earnings Before Interest and Taxes (EBIT) margin* was 16.1% versus the fourth quarter of 2022 Standalone Adjusted EBIT margin* of 16.1% Cash flow from operating activities was $1.1 billion versus $1.1 billion for the prior year; Free cash flow* was $956 million versus $987 million; repaid $850 million of debt in the fourth quarter of 2023 and an additional $150 million of debt in January 2024 Full Year 2023 Revenue growth was 7% year-ove
GE HealthCare (NASDAQ:GEHC), a leader in precision care innovation, will announce its fourth quarter and full year 2023 financial results before the market opens on Tuesday, February 6, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay will also all be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digita
The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the fourth quarter of 2023 payable on February 15, 2024 to all shareholders of record as of January 16, 2024. About GE HealthCare GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and c
Revenue growth was 5% year-over-year; Organic revenue growth* of 6% Net income attributable to GE HealthCare was $375 million versus $487 million for the prior year; Adjusted EBIT* $744 million versus $700 million Net income margin was 7.8% versus 10.6% for the prior year; Adjusted EBIT margin* was 15.4% versus Standalone EBIT margin* of 14.2% Diluted EPS was $0.83 versus $1.07 for the prior year; Adjusted EPS* was $0.99 versus Standalone Adjusted EPS* of $0.87 Cash flow from operating activities was $650 million versus $622 million for the prior year; Free cash flow* was $570 million versus $548 million The Company raises low end of full-year Adjusted EPS* guidance range